The purpose of this study is to determine if adding Memantine can improve the treatment of negative symptoms in patients with first episode psychosis. The study will last for 12 weeks and is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or a placebo. Participants will be randomly assigned to receive either Memantine or a placebo in addition to their regular antipsychotic medication. The main goal is to see if there is a reduction in negative symptoms after 12 weeks of treatment.

Throughout the study, changes in cognitive functions like memory and attention will also be monitored, along with overall clinical measures and any side effects. The study will also explore how Memantine affects certain brain regions involved in psychosis. This research aims to provide a better understanding of how to effectively treat negative symptoms in psychosis, potentially improving the quality of life for those affected by this condition.

The purpose of the study is to explore how GT-002 affects certain brain activities in people with schizophrenia. Participants will receive either GT-002, oxazepam, or a placebo and will undergo tests to measure changes in brain function and mood. These tests include monitoring brain waves using a method called EEG, which records electrical activity in the brain, and other assessments to understand how the treatment impacts thinking and attention.

The study will take place over a short period, and participants will be closely monitored for any side effects or changes in their condition. The goal is to gather information on the safety and effectiveness of GT-002 in improving cognitive function in people with schizophrenia, which could lead to better treatment options in the future.

The purpose of the study is to determine if there is a difference in the effectiveness of these two treatment strategies based on the type of psychotic symptoms a patient experiences. The study will last for up to 24 months, during which patients will be monitored to see how well they function in their daily lives. This will be assessed using a scale called the Personal and Social Performance Scale (PSP). Patients will have regular check-ins with their healthcare providers and a specialized evaluation team to track their progress.

Throughout the study, various aspects of the patients’ health will be monitored, including any side effects from the medications, their overall well-being, and their quality of life. The study aims to provide insights into how personalized treatment plans can improve outcomes for individuals with schizophrenia spectrum disorders. The ultimate goal is to find the most effective way to manage these conditions while minimizing side effects and improving patients’ quality of life.

The trial involves comparing the effects of ITI-1284 with a placebo, which looks like the real medication but does not contain the active ingredient. Participants in the study will take the medication once daily for a period of six weeks. During this time, researchers will monitor changes in the participants’ symptoms to determine how well the medication works in reducing the symptoms of psychosis.

The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The goal is to provide a clearer understanding of the potential benefits and safety of ITI-1284 for individuals with psychosis related to Alzheimer’s disease.

During the study, participants will receive either KarXT capsules or placebo capsules to take by mouth. The medication or placebo will be given over a period of several weeks to determine if KarXT helps improve the psychotic symptoms that can occur with Alzheimer’s disease. The study will compare how well KarXT works compared to the placebo in reducing these symptoms.

Before joining the study, participants will need to have brain imaging done using either magnetic resonance imaging (MRI) or computed tomography (CT) to confirm their diagnosis. Throughout the study, doctors will monitor the participants’ symptoms and overall health to evaluate how well the treatment is working and ensure their safety.

The trial will use several medications, including Folinoral (containing calcium folinate), Omacor (containing omega-3-acid ethyl esters 90), Vitamine B12 Gerda (containing cyanocobalamin), and Mucodrill (containing acetylcysteine). These medications will be administered over a period of up to 12 weeks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications.

The study will monitor participants’ progress from the start to three months later, using a tool called the Personal and Social Performance (PSP) Scale to measure improvements in their ability to function in daily life. This trial is designed to provide insights into how personalized care can benefit those with early psychosis, potentially leading to better treatment strategies in the future.

Participants in the study will be randomly assigned to either continue their current antipsychotic medication or to gradually reduce or stop it. The study will monitor various aspects of their health and well-being, including any side effects from the medication, overall quality of life, and any changes in their physical and mental health. The study will also look at how these changes affect their ability to function in daily life, including their social interactions and personal well-being.

The study will take place over several years, with regular check-ins to assess the participants’ progress. The primary focus is on long-term social recovery, which is considered important by both patients and their families. Additional factors being monitored include the severity of any remaining symptoms, physical health indicators like body mass index, and any instances of aggression or self-harm. The study aims to provide valuable insights into the best treatment strategies for individuals recovering from a first episode of psychosis.

The purpose of the study is to determine if CBD can help reduce the symptoms of cannabis use relapse in patients who are already receiving antipsychotic treatment. Participants will be randomly assigned to receive either CBD or a placebo, in addition to their regular antipsychotic medication. The study will last for six months, during which participants will be monitored for changes in their symptoms and overall health. Regular assessments will be conducted to track the progress of each participant, and the results will be analyzed to see if there is a significant difference between the group receiving CBD and the group receiving the placebo.

Throughout the study, participants will continue their treatment with aripiprazole, which may be switched from oral to long-acting injection form. The trial aims to provide insights into whether CBD can be a beneficial addition to existing treatments for young individuals dealing with substance-induced psychosis and cannabis use disorder. The findings could potentially lead to improved treatment strategies for managing these conditions.

The purpose of the study is to evaluate whether Rituximab can be a clinically effective treatment for patients with these conditions. During the study, participants will receive either Rituximab or a placebo. The study will monitor changes in symptoms over time to determine the effectiveness of the treatment. Participants will be observed for improvements in their psychiatric and neurological symptoms, as well as any changes in their overall health and well-being.

The study will last for several months, with regular check-ups to assess the participants’ progress. The safety of Rituximab will also be closely monitored throughout the trial. This research aims to provide valuable insights into whether Rituximab can help patients with Psychosis or OCD when the immune system is involved, potentially leading to better treatment options in the future.

The purpose of the study is to compare how well patients respond to medication doses that are personalized based on their genetic makeup, known as pharmacogenetics, versus the usual dosing methods. Participants will be randomly assigned to receive either the personalized dosing or the usual dosing, which may include a placebo. The study will last for 24 weeks, during which participants will take the medication orally in the form of tablets. Throughout the study, participants’ recovery, well-being, and quality of life will be monitored, along with any side effects they may experience.

Pharmacogenetics is a field of medicine that looks at how a person’s genes can affect their response to drugs. By understanding these genetic differences, doctors can tailor treatments to each individual, potentially improving the effectiveness of the medication and reducing side effects. This study aims to see if using pharmacogenetics can lead to better outcomes for patients with these mental health conditions.

The purpose of this study is to understand how safe KarXT is when used over a long period and how well it is tolerated by participants. Participants in the study will take the medication orally, meaning by mouth, in capsule form. The study will last for up to 52 weeks, during which participants will be monitored for any side effects or changes in their condition. Some participants may receive a placebo, which is a capsule that looks like the medication but does not contain the active substances.

Throughout the study, researchers will keep track of any side effects, known as treatment-emergent adverse events (TEAEs), that participants experience. They will also monitor for any serious side effects or any that might lead to stopping the medication. This information will help determine the long-term safety and tolerability of KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to provide valuable insights into the potential benefits and risks of using KarXT for this condition.

The purpose of the study is to evaluate whether adding oxytocin to the usual psychosocial treatment can improve social skills in individuals with schizophrenia spectrum disorders. Participants in the study will receive either the oxytocin nasal spray or the placebo, in addition to their regular psychosocial treatment. The study will last for a period of 12 weeks, during which the effects of the treatment on social skills and overall functioning will be monitored.

Throughout the study, researchers will assess changes in personal and social performance, as well as other aspects such as quality of life and cognitive function. The goal is to determine if oxytocin can be a beneficial addition to existing treatments for improving social interactions and quality of life for those living with schizophrenia spectrum disorders.

The main purpose of this research is to determine if cannabidiol is effective in treating psychosis symptoms. The study focuses on people who have various types of psychotic disorders, including schizophrenia, paranoid psychosis, acute psychotic disorder, schizoaffective psychosis, and cannabis-induced psychotic disorder.

During the study, which lasts seven weeks, participants will take either cannabidiol (up to 600 mg per day), risperidone (up to 4 mg per day), or placebo. The study will monitor various aspects of participants’ health, including severity of psychotic symptoms, cannabis use patterns, sleep quality, and overall well-being.